Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states

被引:66
|
作者
Wen, Feng [1 ,2 ]
Zheng, Hanrui [2 ,3 ]
Zhang, Pengfei [1 ,2 ]
Liao, Weiting [1 ,2 ]
Zhou, Kexun [1 ,2 ]
Li, Qiu [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[2] Sichuan Univ, West China Biostat & Cost Benefit Anal Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Clin Pharm, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
atezolizumab and bevacizumab; cost‐ effectiveness; first‐ line systemic treatment; unresectable hepatocellular carcinoma; PRIMARY LIVER-CANCER; HEPATITIS-B-VIRUS; THERAPIES;
D O I
10.1111/liv.14795
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims In patients with unresectable hepatocellular carcinoma (HCC), the combination of atezolizumab and bevacizumab improved progression-free survival (PFS) and overall survival compared with sorafenib in the IMbrave150 trial. However, whether the price of the combination could be affordable is unknown. The current study assessed the cost-effectiveness of the combination of atezolizumab and bevacizumab as first-line systemic therapy for patients with unresectable HCC from the Chinese and American payers' perspective. Methods A Markov model was built based on a global, multicentre, open-label, phase III randomized trial (IMbrave150, NCT03434379) that included three states of the patient's health: stable disease (SD), progressive disease (PD) and death. Data for all medical costs were acquired from the Red Book, published literature and West China Hospital. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) were the primary outcomes. Sensitivity analyses were performed to evaluate the model uncertainty. Results The treatment consisting of a combination of atezolizumab and bevacizumab yielded an additional 0.53 QALYs compared with sorafenib alone, leading to an ICER of $145,546.21 per QALY in China and $168,030.21 per QALY in the USA, both beyond the willing-to-pay threshold ($28,527.00/QALY in China and $150,000.00 /QALY in the USA). The utility of the PD state was the most influential factor in the Chinese model, and the American model was the most sensitive to the price of sorafenib. The results of the models were robust across sensitivity analyses. Conclusion The combination of atezolizumab and bevacizumab was not a cost-effective strategy for the first-line systemic treatment of unresectable HCC from the Chinese and American payers' perspective.
引用
收藏
页码:1097 / 1104
页数:8
相关论文
共 50 条
  • [41] The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
    Trueman, David
    Liu, Yifeng
    Geadah, Marc
    Hon, Nicholas
    Sabapathy, Suthakar
    Kamboj, Laveena
    Li, Huimin
    Lucero, Melanie
    Meier, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (08) : 1389 - 1397
  • [43] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Olaparib in combination with bevacizumab compared to bevacizumab monotherapy for the first-line maintenance treatment of advanced ovarian cancer: a cost-effectiveness analysis
    Fan, Lin
    Muston, Dominic
    Elsea, David
    El Moustaid, Fadoua
    Mihai, Adela
    Simmons, Daniel
    McLaurin, Kimmie
    Monberg, Matthew
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S216 - S217
  • [46] Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
    Mohri, Kunihide
    Nagai, Hidenari
    Matsuda, Takahisa
    Igarashi, Yoshinori
    Higai, Koji
    ANTICANCER RESEARCH, 2024, 44 (09) : 3919 - 3929
  • [47] Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    ONCOLOGIST, 2020, 25 (03): : E512 - E519
  • [48] Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma
    Wang, Siying
    Xie, Ouyang
    Wu, Meiyu
    Xiang, Heng
    Tan, Chongqing
    Wan, Xiaomin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 173 - 178
  • [49] First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Mahipal, Amit
    Jin, Zhaohui
    BIOMEDICINES, 2022, 10 (06)
  • [50] ASSESSING THE COST-EFFECTIVENESS OF LENVATINIB AS A FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CANADA
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E3 - E4